Abdominal Aortic Aneurysm
An abdominal aortic aneurysm is a degenerative disease process of the infrarenal aorta in which the aorta becomes increasingly dilated with eventual rupture. Protheragen's mission is to change the landscape of rare cardiovascular disease therapy. Our full-solution, all-inclusive service platform will guide and support you through the entire drug development process, from discovery to market conversion.
Introduction to Abdominal Aortic Aneurysm
An abdominal aortic aneurysm is a pathological condition of the abdominal aorta in which the aorta distends to a diameter of 3.0 cm or more, and is at an increased risk of rupture. Abdominal aortic aneurysm is at least nine times more common than thoracic aortic aneurysm. Several studies have demonstrated that aneurysms of the aorta are commonly inherited, even when they are not related to rare heritable disorders.
Fig.1 The pathogenesis and therapy of abdominal aortic aneurysms. (Golledge, J., et al., 2022)Pathogenesis of Abdominal Aortic Aneurysm
The natural history of abdominal aortic aneurysm is a usually asymptomatic enlargement of the diameter of the aorta, resulting from a complex aortic wall degeneration, and culminates in rupture of the aorta. Familial abdominal aortic aneurysm is caused by genetic mutations, and pathogenic mutations have been identified. Genetic mutations can be inherited when parents pass them on to their children, but they can also arise spontaneously as cells divide. In addition, genetic changes can occur as a result of acquired viruses, exposure to environmental factors such as UV light from the sun, and a combination of these.
Therapeutics Development for Abdominal Aortic Aneurysm
| Drug Name | Mechanism of Action | Targets | Research Phase |
|---|---|---|---|
| Hexarelin | Rescue the contractile phenotype of smooth muscle cells in terms of higher α-SMA and lower MMP2. | GHSR | Preclinical |
| ADSCs | Inhibit the inflammation of the abdominal aorta and expansion of the aneurysm by paracrine factors. | miR-17-5p | Preclinical |
| Terazosin | By downregulating the expression of Peg3, which suppressed vascular smooth muscle cell apoptosis and aging, and decreased the MMP level. | α1-adrenoceptor | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
The partnership services of our company are focused and designed to meet the diverse needs of rare cardiovascular drug development. In diagnostics, we apply the latest technologies to discover new biomarkers and to develop accurate diagnostic tools that enable the early detection of disease. For therapeutics, we offer full service from target validation to lead optimization and preclinical efficacy testing. Indeed, while our disease model construction services are the crux of our services and we also offer all preclinical research services, including pharmacokinetics and drug safety studies.
Therapeutic Development Services
Diverse Platforms
Animal Model Development for Abdominal Aortic Aneurysm
Appropriate animal models of abdominal aortic aneurysm are important for the study of the complex pathogenesis of this disease, for the discovery of potential therapeutic targets, and for the testing of novel interventions. We develop and validate more relevant preclinical model systems, including animal models for abdominal aortic aneurysm that genuinely recapitulate the human disease process and allow rigorous validation of therapeutic agents.
These models usually require the direct application of enzymes or vasoactive factors to the aorta, often in the presence of chemical stimuli, to induce local inflammation and extracellular matrix degradation, followed by aneurysm formation.
- Elastase-induced Model
- Calcium chloride or phosphate-induced Model
- E-BAPN-induced Model
- Angiotensin II-induced Model
By uniting scientific brilliance, technological innovation, and a client-centric approach, Protheragen helps our partners to unlock new therapies that can save lives. From novel disease models and diagnostic biomarkers to preclinical candidate drug research, we have the skill sets and capabilities to move your program forward with certainty. Get in touch with us for revolutionary solutions that meet the needs of research and enhance efficacy for individuals around the globe.
References
- Golledge, Jonathan et al. "Mouse models for abdominal aortic aneurysm." British journal of pharmacology 179.5 (2022): 792-810.
- Accarino, Giulio et al. "Abdominal Aortic Aneurysm: Natural History, Pathophysiology and Translational Perspectives." Translational medicine UniSa 24.2 (2022): 30-40.
For research use only, not for clinical use.